Stay updated with breaking news from Thomas Baumert. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The trial confirms ALE.F02's good safety profile, exposure and target biological activity Alentis Therapeutics ("Alentis"), the clinical-stage biotechnology company developing breakthrough treatments
Proceeds will fund:- Clinical programs ALE.F02 and ALE.C04 – two first-in-class anti-Claudin-1 (CLDN1) antibodies for organ fibrosis and CLDN1 positive tumors- The platform to engineer CLDN1 antibody drug conjugates (ADC) and bi-specific antibodiesBASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”)...
Alentis Therapeutics ("Alentis"), the Claudin-1 (CLDN1) company, is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. Today, Alentis announced $105 million in Series C financing. The funding...
/PRNewswire/ -- Novo Holdings A/S, a leading international life sciences investor, today announced it has participated in a new investment in the US$105...
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1